MENOPUR
**The essential choice for quality**

TRUSTED TO DELIVER DESIRED OUTCOMES FOR ASPIRING PARENTS OVER 20 YEARS^1-4

The MENOPUR difference

The only FDA-approved highly purified human menopausal gonadotropin containing
75 International Units (IU) FSH and 75 IU hCG-driven LH activity^5,6

FSH

follicle-stimulating hormone

hCG-Driven LH Activity

luteinizing hormone

hCG=human chorionic gonadotropin.

Proven safe and
well-tolerated

MENOPUR demonstrated similar safety when compared to rFSH.

The most common adverse reactions (≥2%) include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.⁶

Most common adverse events in Study 1¹ (occurring in over 0.3% of participants)

Adverse Event	MENOPUR (n=373)	rFSH (n=354)
Ovarian hyperstimulation	7.0%	5.1%
Abdominal pain	6.4%	7.1%
Inflammation at injection site	4.8%	3.4%
Pain at injection site	4.6%	3.7%
Headache	3.8%	2.8%
Enlarged abdomen	2.7%	0.6%
Nausea	1.9%	0.3%
Reaction at injection site	1.3%	0.8%

Most common adverse events in Study 2² (occurring in over 2.0% of participants)

Adverse Event	MENOPUR (n=363)	rFSH (n=368)
Abortion	9%	10%
Pelvic pain	6%	6%
Headache	5%	5%
Post-procedural pain	3%	4%
Ovarian hyperstimulation syndrome	4%	3%
Nausea	2%	4%
Abdominal distension	2%	3%

rFSH=recombinant follicle-stimulating hormone; OHSS=ovarian hyperstimulation syndrome.

**The broadest insurance coverage of any gonadotropin¹¹**

MENOPUR is covered by 90% of commercial benefits packages¹¹

Coverage as of 6/25. Please note: Subject to change based on individual plan coverage.
Check the member’s benefits for more details.

Explore Resources

The journey starts with 225 IU of MENOPUR⁶

Each vial contains 75 IU of FSH and
hCG-driven LH activity^5,6

Request a sample

MENOPUR® (menotropins for injection) vials

References: 1. European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78:520–8. doi: 10.1016/S0015-
0282(02)03250-8 2. Andersen AN, Devroey P, Arce JC. MERIT Group. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21(12):3217-27. doi: 10.1093/
humrep/del284 3. Devroey P, Pellicer A, Andersen AN, Arce JC. Menopur in GnRH Antagonist Cycles with Single Embryo Transfer Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97(3):561-71. doi: 10.1016/
j.fertnstert.2011.12.016 4. Witz CA, Daftary GS, Doody KJ. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertil Steril. 2020;114(2):321-330. doi: 10.1016/ j.fertnstert.2020.03.029 5. Wolfenson C, Groisman J, Couto AS, et al. Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online. 2005;10(4):442-54. doi: 10.1016/s1472-6483(10)60819-x 6. MENOPUR (menotropins for injection) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 7. Smitz J, Andersen AN, Devroey P, Arce JC. MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2007;22(3):676-87. doi: 10.1093/humrep/del445
 8. Ziebe S, Lundin K, Janssens R, Helmgaard L, Arce JC. MERIT Group. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Hum Reprod. 2007;22(9):2404-13. doi: 10.1093/humrep/
dem221 9. Arce JC, La Marca A, Klein BM, Andersen AN, Fleming R. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril. 2013;99(6):1644-53. doi: 10.1016/j.fertnstert.2012.12.048 10. Arce JC, Klein BM, La Marca A. The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin. Gynecol Endocrinol. 2014;30(6):444-50. doi: 10.3109/09513590.2014.892066 11. Data on File. Ferring Pharmaceuticals Inc.

IMPORTANT SAFETY INFORMATION

MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman.
MENOPUR should only be used by physicians who are thoroughly familiar with infertility problems. MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with MENOPUR.
The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.

INDICATION FOR USE

MENOPUR^® (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted Reproductive Technology (ART) program.

You are encouraged to report negative side effects of prescription drugs to FDA.
Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.

Please see full Prescribing Information.

MENOPUR The essential choice for quality

The safety and efficacy of MENOPUR have been demonstrated in multiple publications from 4 clinical trials1-4, 7-10

The MENOPUR difference

FSH

hCG-Driven LH Activity

Proven safe and well-tolerated

Most common adverse events in Study 11 (occurring in over 0.3% of participants)

Most common adverse events in Study 22 (occurring in over 2.0% of participants)

The broadest insurance coverage of any gonadotropin11

The journey starts with 225 IU of MENOPUR6

You are now leaving the website. Would you like to continue?

MENOPUR
**The essential choice for quality**

The safety and efficacy of MENOPUR have been demonstrated in multiple publications from 4 clinical trials^{1-4, 7-10}

Proven safe and
well-tolerated

Most common adverse events in Study 1¹ (occurring in over 0.3% of participants)

Most common adverse events in Study 2² (occurring in over 2.0% of participants)

**The broadest insurance coverage of any gonadotropin¹¹**

The journey starts with 225 IU of MENOPUR⁶

You are now leaving the website.
Would you like to continue?